Chronic lymphocytic leukemia differential diagnosis

Jump to navigation Jump to search

Chronic lymphocytic leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Chronic lymphocytic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Chronic lymphocytic leukemia differential diagnosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Chronic lymphocytic leukemia differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Chronic lymphocytic leukemia differential diagnosis

CDC on Chronic lymphocytic leukemia differential diagnosis

Chronic lymphocytic leukemia differential diagnosis in the news

Blogs on Chronic lymphocytic leukemia differential diagnosis

Directions to Hospitals Treating Chronic lymphocytic leukemia

Risk calculators and risk factors for Chronic lymphocytic leukemia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Differential diagnosis

Hematologic disorders that may resemble CLL in their clinical presentation, behavior, and microscopic appearance include:

All the B cell malignancies of the blood and bone marrow can be differentiated from one another by the combination of cellular microscopic morphology, marker molecule expression, and specific tumor-associated gene defects. This is best accomplished by evaluation of the patient's blood, bone marrow and occasionally lymph node cells by a pathologist with specific training in blood disorders. A sophisticated instrument called a flow cytometer is necessary for cell marker analysis and the detection of genetic problems in the cells may require visualizing the DNA changes with fluorescent probes by fluorescent in situ hybridization (FISH). CLL is positive for CD5, CD19 & CD23; CLL is the only cell type that coexpresses CD5 & 19. It is negative for CD10 & cyclin D. CD20 is +/- as is sIg. 90% of B-CLL have bcl-2. The 2 most noteworthy lymphoproliferative diseases with CD5 positivity are CLL (which is CD23 positive) & mantle zone lymphoma (which is CD23 negative). Other CD5+ groups include peripheral & cutaneous T-cell lymphoma, lymphoblastic lymphoma, and adult T-cell leukemia/lymphoma.

References

Template:Hematology


Template:WikiDoc Sources